Teva Buys Majority Stake In Japanese Generics Company For $460 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
The world's largest maker of generic drugs buys access to the rapidly growing Japanese generics market with the acquisition of Taiyo Pharmaceuticals.
You may also be interested in...
Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.
Former “String Of Pearls” Strategist Tabbed To Lead Teva’s Continuing Diversification
Jeremy Levin, who left Bristol-Myers Squibb on Jan. 1, will succeed outgoing Teva CEO Shlomo Yanai in May, as the Israeli generics giant seeks to increase its emphasis on branded drugs.
Teva Stakes OTC Claim With P&G Joint Venture
Teva is making a big push into OTCs, announcing a joint venture with Procter & Gamble to combine OTC businesses outside North America.